Emergent BioSolutions Inc. (EBS)

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma antitoxin for the treatment of symptomatic botulism; BioThrax, an anthrax vaccine; CYFENDUS, a vaccine for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; Ebanga, a monoclonal antibody for the treatment of infection caused by Orthoebolavirus zairense; Raxibacumab injection, a monoclonal antibody therapeutic for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis; TEMBEXA, an oral antiviral for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; and CNJ-016, a polyclonal antibody therapeutic to address complications from smallpox vaccination. It also provides NARCAN and KLOXXADO nasal sprays for the emergency treatment of known or suspected opioid overdose. In addition, the company offers contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, analytical development, and suite reservation services. Emergent BioSolutions Inc. was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.

Super investor ownership

6 of the funds we track reported a position in their latest SEC 13F filing. Largest first:

• Israel Englander, MILLENNIUM MANAGEMENT LLC$8.98M · 0.0% of book
• Cliff Asness, AQR CAPITAL MANAGEMENT LLC$8.72M · 0.0% of book
• D. E. Shaw, D. E. Shaw & Co., Inc.$7.54M · 0.0% of book
• Renaissance Technologies, RENAISSANCE TECHNOLOGIES LLC$5.73M · 0.0% of book
• Two Sigma, TWO SIGMA INVESTMENTS, LP$4.09M · 0.0% of book

A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.

Politician trades in EBS

Trades in EBS disclosed by members of Congress and executive-branch officials, latest first:

• Gilbert Cisneros · HouseBuy · $1,001 - $15,000 · traded 24 Nov 2020 · disclosed 15 Dec 2020
• Gilbert Cisneros · HouseBuy · $1,001 - $15,000 · traded 30 Jul 2020 · disclosed 19 Aug 2020
• Gilbert Cisneros · HouseBuy · $1,001 - $15,000 · traded 30 Jun 2020 · disclosed 17 Jul 2020
• Gilbert Cisneros · HouseBuy · $1,001 - $15,000 · traded 19 Jun 2020 · disclosed 17 Jul 2020

A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.

Common questions